Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Non-Small-Cell Lung 6Neoplasm, Residual 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Plasma Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Fallopian Tube Neoplasms 1

Interventions

Rituximab 295Cyclophosphamide 240Peripheral Blood Stem Cell Transplantation 114fludarabine phosphate 110Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 79Vincristine 78Prednisone 77Mycophenolic Acid 66Doxorubicin 61Cyclosporine 59Whole-Body Irradiation 58Bendamustine Hydrochloride 58Melphalan 57Tacrolimus 53Busulfan 51fludarabine 50Cytarabine 48obinutuzumab 46Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 32ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Follicular × Maintenance × Clear all
NCT04542824 2026-05-05

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02063685 2022-06-21

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Fondazione Italiana Linfomi - ETS

Phase 3 Completed
807 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡